[go: up one dir, main page]

SG11201403771SA - New c5a binding nucleic acids - Google Patents

New c5a binding nucleic acids

Info

Publication number
SG11201403771SA
SG11201403771SA SG11201403771SA SG11201403771SA SG11201403771SA SG 11201403771S A SG11201403771S A SG 11201403771SA SG 11201403771S A SG11201403771S A SG 11201403771SA SG 11201403771S A SG11201403771S A SG 11201403771SA SG 11201403771S A SG11201403771S A SG 11201403771SA
Authority
SG
Singapore
Prior art keywords
new
nucleic acids
binding nucleic
binding
acids
Prior art date
Application number
SG11201403771SA
Inventor
Kai Höhlig
Axel Vater
Klaus Buchner
Christian Maasch
Sven Klussmann
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/000089 external-priority patent/WO2012095303A1/en
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Publication of SG11201403771SA publication Critical patent/SG11201403771SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/344Position-specific modifications, e.g. on every purine, at the 3'-end
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4716Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
SG11201403771SA 2012-01-10 2013-01-10 New c5a binding nucleic acids SG11201403771SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12000106 2012-01-10
PCT/EP2012/000089 WO2012095303A1 (en) 2011-01-10 2012-01-10 Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
EP12006960 2012-10-08
PCT/EP2013/000056 WO2013104540A1 (en) 2012-01-10 2013-01-10 New c5a binding nucleic acids

Publications (1)

Publication Number Publication Date
SG11201403771SA true SG11201403771SA (en) 2014-07-30

Family

ID=48781063

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201403771SA SG11201403771SA (en) 2012-01-10 2013-01-10 New c5a binding nucleic acids
SG10201605594UA SG10201605594UA (en) 2012-01-10 2013-01-10 New c5a binding nucleic acids

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201605594UA SG10201605594UA (en) 2012-01-10 2013-01-10 New c5a binding nucleic acids

Country Status (18)

Country Link
US (4) US9518265B2 (en)
EP (1) EP2802660B1 (en)
JP (1) JP6415327B2 (en)
KR (1) KR102034203B1 (en)
CN (1) CN104145018B (en)
AU (2) AU2013209131A1 (en)
BR (1) BR112014016877B1 (en)
CA (1) CA2860806C (en)
DK (1) DK2802660T3 (en)
ES (1) ES2786007T3 (en)
IL (1) IL233516B (en)
IN (1) IN2014DN05665A (en)
MX (1) MX362061B (en)
PL (1) PL2802660T3 (en)
PT (1) PT2802660T (en)
RU (1) RU2645261C2 (en)
SG (2) SG11201403771SA (en)
WO (1) WO2013104540A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105849323A (en) 2013-10-28 2016-08-10 多茨设备公司 Allergen detection
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US11172873B2 (en) 2018-05-17 2021-11-16 The Procter & Gamble Company Systems and methods for hair analysis
MX2020012225A (en) 2018-05-17 2021-01-29 Procter & Gamble Systems and methods for hair coverage analysis.
EP3586865A1 (en) * 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
US11384357B2 (en) 2018-06-29 2022-07-12 The Procter And Gamble Company Aptamers for personal care applications
WO2020098968A1 (en) * 2018-11-12 2020-05-22 Aptarion Biotech Ag Cxcl8 binding nucleic acids
WO2020214784A1 (en) 2019-04-16 2020-10-22 The Procter & Gamble Company Aptamers for odor control applications
US12039732B2 (en) 2021-04-14 2024-07-16 The Procter & Gamble Company Digital imaging and learning systems and methods for analyzing pixel data of a scalp region of a users scalp to generate one or more user-specific scalp classifications
CN113150106B (en) * 2021-04-26 2022-08-16 华中农业大学 Antibacterial peptide derived from complement component C5a and application thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6140490A (en) 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
EP1306382A1 (en) 2001-10-26 2003-05-02 Noxxon Pharma AG Modified L-nucleic acids
EP1438321B1 (en) 2001-10-26 2010-05-26 Noxxon Pharma AG Modified l-nucleic acid
DE60329126D1 (en) 2002-02-20 2009-10-15 Beth Israel Hospital CONJUGATES OF BIODEGRADABLE POLYMER AND USE THEREOF
KR20060015505A (en) 2003-04-13 2006-02-17 엔존 파마슈티컬즈, 인코포레이티드 Oligonucleotide Prodrugs
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20090281296A1 (en) 2004-02-09 2009-11-12 Supramol Parenteral Colloid Gmbh Process for the production of conjugates from polysaccharides and polynucelotides
EP3385384B1 (en) 2004-02-12 2020-04-08 Archemix LLC Aptamer therapeutics useful in the treatment of complement-related disorders
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
ES2741524T3 (en) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Polymeric prodrug with an auto-immolator linker
EP1807092B1 (en) 2004-11-05 2016-09-07 The Children's Hospital of Philadelphia Biodegradable linkers for molecular therapies
RU2007131267A (en) * 2005-01-17 2009-02-27 Йерини Аг (De) C5a RECEPTOR ANTAGONISTS
PL1991275T3 (en) 2006-03-08 2015-04-30 Archemix Llc Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
CN101534643A (en) 2006-09-15 2009-09-16 安佐制药股份有限公司 Hindered ester-based biodegradable linkers for oligonucleotide delivery
WO2008052774A2 (en) 2006-10-31 2008-05-08 Noxxon Pharma Ag Methods for detection of a single- or double-stranded nucleic acid molecule
WO2009040113A2 (en) 2007-09-24 2009-04-02 Noxxon Pharma Ag C5a BINDING NUCLEIC ACIDS
JP4642940B2 (en) 2009-03-11 2011-03-02 オリンパスメディカルシステムズ株式会社 Image processing system, external device thereof, and image processing method thereof
WO2010108657A2 (en) 2009-03-23 2010-09-30 Noxxon Pharma Ag C5a binding nucleic acids and the use thereof
CN102906265B (en) 2010-04-21 2016-08-24 诺松制药股份公司 Lipid binding nucleic acid
CA2824073A1 (en) * 2011-01-10 2012-07-19 Noxxon Pharma Ag Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
AU2012325233A1 (en) 2011-10-21 2014-04-24 Noxxon Pharma Ag Glucagon binding nucleic acids
WO2013104539A1 (en) 2012-01-10 2013-07-18 Noxxon Pharma Ag Nucleic acids specifically binding cgrp

Also Published As

Publication number Publication date
IL233516B (en) 2018-07-31
MX2014008454A (en) 2015-02-05
MX362061B (en) 2019-01-07
US20240384275A1 (en) 2024-11-21
PT2802660T (en) 2020-04-21
US11492625B2 (en) 2022-11-08
US20210163946A1 (en) 2021-06-03
AU2018271388B2 (en) 2021-03-11
CA2860806A1 (en) 2013-07-18
AU2013209131A1 (en) 2014-07-10
US20180223285A1 (en) 2018-08-09
PL2802660T3 (en) 2020-07-27
BR112014016877A2 (en) 2019-10-29
US10590424B2 (en) 2020-03-17
KR20140111703A (en) 2014-09-19
JP2015509705A (en) 2015-04-02
US20140364487A1 (en) 2014-12-11
ES2786007T3 (en) 2020-10-08
US9518265B2 (en) 2016-12-13
SG10201605594UA (en) 2016-09-29
CA2860806C (en) 2020-10-20
RU2645261C2 (en) 2018-02-19
CN104145018B (en) 2019-05-10
US12188021B2 (en) 2025-01-07
IN2014DN05665A (en) 2015-05-15
AU2018271388A1 (en) 2018-12-20
KR102034203B1 (en) 2019-10-18
JP6415327B2 (en) 2018-10-31
DK2802660T3 (en) 2020-05-18
HK1198371A1 (en) 2015-04-10
EP2802660A1 (en) 2014-11-19
WO2013104540A1 (en) 2013-07-18
BR112014016877B1 (en) 2022-03-15
RU2014132708A (en) 2016-02-27
EP2802660B1 (en) 2020-02-19
IL233516A0 (en) 2014-08-31
CN104145018A (en) 2014-11-12

Similar Documents

Publication Publication Date Title
DK2922554T3 (en) Terminalt modificeret rna
IL231983B (en) Tricyclo-phosphorothioate dna
AP2015008266A0 (en) 1L-18 binding molecules
SG10201800645WA (en) Extreme pcr
EP2922959A4 (en) Tal-mediated transfer dna insertion
EP2717649A4 (en) Heater
GB2506862B (en) Book
IL235325A0 (en) Nucleic acid extraction
IL233516A0 (en) New c5a binding nucleic acids
GB201204407D0 (en) Nucleic acid molecule
PL2928936T3 (en) Binder
PL2928935T3 (en) Binders
PL2870252T3 (en) Methods using patatin
HU4206U (en) Multi purposal sportsdevice
EP2902488A4 (en) Modified dna polymerase
IL233515A0 (en) Nucleic acids specifically binding cgrp
IL231980A0 (en) Glucagon binding nucleic acids
GB2501157B (en) Space heater
EP2868485A4 (en) Binder
EP2844775A4 (en) Dna sequencing
EP2817419A4 (en) Chimeric dna identifier
GB201201849D0 (en) Space heater
PL2631584T3 (en) Heater
GB201208942D0 (en) Extraction control for RNA
GB201200563D0 (en) Binding molecule